The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

According to WHO, 254 million people globally were estimated to have HBV in 2022, but only approximately 10% had been ...

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...

China: A recent retrospective cohort study has highlighted the significant role of pulmonary infections in influencing ...

Chronic hepatitis B infection is primarily driven by persistence of HBV cccDNA and integration of HBV DNA into the human genome in liver cells, the primary source of hepatitis B surface antigen ...

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

The treatment of chronic hepatitis B disease has improved dramatically in the last 10 years, owing to the development of new antiviral compounds targeting hepatitis B virus (HBV) polymerase ...

Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...